文献速递心律失常

脉冲电场消融增强肺静脉隔离持久性并治疗阵发性房颤

Pulsed-Field Ablation to Enhance the Durability of Pulmonary Vein Isolation and Treat Paroxysmal Atrial Fibrillation.
PubMed 文献 · J Am Coll Cardiol · 2026-01-21

PULSAR 多中心单臂关键试验纳入 183 例有症状、药物抵抗或不耐受的阵发性房颤患者,使用球形阵列脉冲电场消融导管完成肺静脉隔离。12 个月主要有效性终点为 77.8%(95%CI:70.6%–83.9%),主要安全性事件率为 0.6%。重复消融患者中 95.1% 的肺静脉仍保持持久隔离。

要点

  • 该球形阵列 PFA 系统首次脉冲放电即实现 94%(607/647)肺静脉电隔离。
  • 12 个月无房性心律失常率为 77.8%,主要安全性事件率仅 0.6%。
  • 重复消融时 95.1%(39/41)肺静脉仍持久隔离,提示消融效果持久。

核心结论

  • 该新型 PFA 导管在 FDA 试验中展现的良好临床成功率,反映了阵发性房颤患者持久肺静脉隔离可实现的临床获益。

研究设计与样本

  • PULSAR 为多中心单臂关键性器械豁免试验,入组 183 例患者,包括 19 例导入患者和 164 例关键试验患者。
  • 患者平均年龄 65±9.1 岁,40% 为女性,CHA2DS2-VASc 评分 2.1±1.4,左房内径 3.8±0.6 cm。
  • 纳入有症状、药物抵抗或不耐受的阵发性房颤患者,使用球形阵列系统完成肺静脉隔离。

主要发现

  • 大多数肺静脉(94%,607/647)经首次脉冲电场放电即达到电隔离。
  • 12 个月主要有效性终点为 77.8%(95%CI:70.6%–83.9%)。
  • 11 例接受重复消融的患者中,41 根肺静脉中有 39 根(95.1%)仍保持持久隔离。
  • 标测时间 9.0±5.5 分钟,透壁消融时间 25.6±9.8 分钟,左房导管停留时间 59.9±11.6 分钟,手术时间 95.8±20.7 分钟。
  • 肺静脉狭窄亚组研究未发现中度或重度静脉狭窄患者。

关键数值与推荐

  • 主要有效性终点为 12 个月无房性心律失常(通过每周及症状驱动的经电话监测和 24 小时动态心电图评估)且无其他失败模式。
  • 其他失败模式包括未能达到肺静脉隔离、重复消融或电复律、以及新增或增加 I 类或 III 类抗心律失常药物剂量。
  • 主要安全性事件率 0.6%(1/164),为 1 例严重高血压合并多囊肾病患者术后即刻出现的出血性卒中。

临床怎么用

  • 球形阵列 PFA 导管可同时完成左房解剖标测、电压标测和肺静脉隔离,手术流程时间较短。
  • 对于药物抵抗或不耐受的阵发性房颤患者,该 PFA 系统可作为实现持久肺静脉隔离的消融选择。
  • 需关注严重高血压合并多囊肾病等特殊人群的术后出血性卒中风险。

局限性

  • 该试验为单臂设计,未设置对照组比较其他消融方式的疗效与安全性。
  • 本研究仅纳入阵发性房颤患者,结果不适用于持续性房颤人群。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In first-in-human studies of the treatment of paroxysmal atrial fibrillation (PAF), a multielectrode globular spherical array pulsed field ablation (PFA) catheter and system able to map, pace, sense contact, and ablate exhibited a high rate, 94%, of durable pulmonary vein isolation (PVI). OBJECTIVES: In this study, the authors sought to assess the 1-year outcomes of a multicenter single-arm pivotal trial of the spherical array system to treat PAF. METHODS: In the multicenter PULSAR pivotal investigational device exemption trial, patients with symptomatic drug-resistant or intolerant PAF underwent PVI with the use of the spherical array system. The array catheter was used to render left atrial anatomy and voltage and perform PVI. The primary effectiveness endpoint was a composite of 12-month freedom from atrial arrhythmias (as assessed by weekly and symptomatic transtelephonic monitoring and 24-hour Holter monitoring) and freedom from other failure modes: failure to achieve PVI, repeated ablation or cardioversion, and the use of new or increased doses of class I or III antiarrhythmic drugs. The primary safety endpoint included primary adverse events within 7 days of the index ablation procedure. RESULTS: The study cohort of 183 patients included 19 roll-in and 164 pivotal patients: aged 65 ± 9.1 years, 40% female, CHA2DS2-VASc 2.1 ± 1.4, left atrial diameter 3.8 ± 0.6 cm. Mapping time (9.0 ± 5.5 min), transpired ablation time (25.6 ± 9.8 min), left atrial catheter dwell time (59.9 ± 11.6 min), and procedure time (95.8 ± 20.7 min) revealed an efficient procedure. Most pulmonary veins (PVs) (94%, 607/647 veins) were electrically isolated by the first pulsed field application. The primary safety event rate was 0.6% (1/164): a hemorrhagic stroke identified immediately after the procedure in a patient with severe hypertension and polycystic kidney disease. The PV stenosis substudy revealed no patients with moderate or severe vein narrowing. Primary effectiveness at 12 months was 77.8% (95% CI: 70.6%-83.9%). During redo ablation in 11 patients, 39 of 41 (95.1%) pulmonary veins remained durably isolated. CONCLUSIONS: The favorable clinical success observed in this multicenter Food and Drug Administration trial of this novel PFA catheter appears to reflect the clinical success achievable with durable PVI in PAF patients. (Safety and Effectiveness of the Globe Pulsed Field System for Treating Patients with Symptomatic Paroxysmal or Persistent Atrial Fibrillation [PULSAR]; NCT05462145).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Reddy, Kottkamp, Calkins, et al. Pulsed-Field Ablation to Enhance the Durability of Pulmonary Vein Isolation and Treat Paroxysmal Atrial Fibrillation. J Am Coll Cardiol. 2026. PMID: 41563170. doi:10.1016/j.jacc.2025.10.084

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。